Published online Sep 26, 2015. doi: 10.5662/wjm.v5.i3.149
Peer-review started: April 2, 2015
First decision: June 3, 2015
Revised: July 6, 2015
Accepted: July 11, 2015
Article in press: July 14, 2015
Published online: September 26, 2015
Refractory chronic cough due to gastroesophageal reflux is a troublesome condition unresponsive to the standard medical anti-reflux therapy. Its underlying mechanisms may include incomplete acid suppression, non-acid reflux, transient lower esophageal sphincter relaxations and esophageal hypersensitivity. The diagnosis of this disorder depends on both the findings of multi-channel intraluminal impedance-pH monitoring and the subsequent intensified anti-reflux therapy. The strategies of pharmacological treatment for refractory chronic cough due to reflux include the optimization of proton pump inhibitors and add-on therapies with histamine H2 receptor antagonists, baclofen and gabapentin. However, the further study is needed to satisfy its management.
Core tip: Refractory cough due to reflux can be defined as a reflux-induced cough resistant to standard medical anti-reflux treatment but responsive to the subsequent intensified anti-reflux therapy. It may be associated with the residual acid or non-acid reflux, transient lower esophageal sphincter relaxations and esophageal hypersensitivity. The definite diagnosis of the disorder depends on the positive findings of multi-channel intraluminal impedance-pH monitoring as well as favorable response to the intensified anti-reflux therapy. The current therapeutic strategies include the complete acid suppression and add-on uses of baclofen or gabapentin.